PIPELINE

ANTICIPATED TIMELINE FOR TELOMIR-1

2025Q2

CMC (Chemistry, Manufacturing, and Controls): Stability, Pharmacology: Characterization & Consolidation

ADME (Absorption, Distribution, Metabolism, and Excretion): : PK/PD (Pharmacokinetics/Pharmaco dynamics) and Formal DMPK (Drug Metabolism and Pharmacokinetics)

ADME: In Vitro Metabolism

Toxicology: Initial
MTD (Maximum Tolerated Dose) Rat/Dog

2025Q3

GMP CMC (Chemistry, Manufacturing, and Controls): : GMP (Good Drug Substance Manufacturing Practice), Stability, Drug product development and Clinical DP (Drug Product) Development

ADME (Absorption, Distribution, Metabolism, and Excretion): : Formal DMPK (Drug Metabolism and Pharmacokinetics)

Toxicology: Formal Toxicology

2025Q4

GMP CMC (Chemistry, Manufacturing, and Controls): : GMP (Good Manufacturing Practice), Drug product and Clinical DP (Drug Product) Manufacturing

Pharmacology: : Consolidation

Toxicology: Formal Toxicology

Regulatory: Prepare IB (Investigator’s Brochure) and IND (Investigational New Drug Application)

2026Q1Toxicology: Completion Formal Toxicology

Regulatory: : Prepare IB (Investigator’s Brochure) and IND (Investigational New Drug Application). IND submission

Clinical: Formal Toxicology

Regulatory: Initiation of Phase-I/II studies

market opportunity

Summary of US Epidemiology

The eligible patient pool analysis for Telomir-1 highlights a potential large patient pool looking for potential treatments to their conditions.

  Total Eligible Population Diagnosed Prevalence Treatment Rate Total Addressable Market
Type 2 Diabetes 34-45M 25-27M 88% $57.47B
Cancer 18M 1.9M Nearly 100% $16.7B
Alzheimer’s Disease 6.5M 6.5M 50% $3.1B
AMD 19.8M 20M Variable. Around 20% $18B

market opportunity for rare diseases

  Total Eligible Population Diagnosed Prevalence Treatment Rate Total Addressable Market
Progeria (Hutchinson-Gilford Progeria Syndrome) 20 children in the U.S. Most cases Limited, Lonafarnib is the only approved drug Minimal
Wilson’s Disease 6-10K Many cases remain undiagnosed. Includes chelating agents like penicillamine and zinc salts. $200-900M
Friedreich’s Ataxia 6K Most cases SKYCLARYSTM (omaveloxolone) is the first FDA-approved treatment. $600.5M, projected to reach 1.71B by 2034
Menkes 16-40 new cases annually Improved detection through genetic testing Includes parenteral copper histidinate administration. Limited

Growth Strategy